Introduction
Recombinant Mouse CD226/DNAM-1 Protein is a genetically engineered protein that is derived from the mouse CD226 gene. This protein plays a crucial role in immune response and is involved in the regulation of T cell activation and cytotoxicity. In this article, we will discuss the structure, activity and applications of this recombinant protein.
Structure of Recombinant Mouse CD226/DNAM-1 Protein
The recombinant mouse CD226/DNAM-1 protein is a type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily. It is composed of a single extracellular domain, a transmembrane domain and a cytoplasmic tail. The extracellular domain consists of two immunoglobulin-like domains, an N-terminal V-type domain and a C-terminal C2-type domain. These domains are responsible for binding to ligands and interacting with other proteins.
Activity of Recombinant Mouse CD226/DNAM-1 Protein
The main function of CD226/DNAM-1 protein is to regulate T cell activation and cytotoxicity. It acts as a co-stimulatory molecule on T cells and enhances their response to antigen stimulation. This protein also plays a crucial role in the activation of natural killer (NK) cells and promotes their cytotoxicity against target cells.
CD226/DNAM-1 protein has been shown to interact with multiple ligands, including CD155, CD112, and CD96. These interactions lead to the activation of downstream signaling pathways, such as the PI3K/AKT and MAPK pathways, which are involved in T cell and NK cell activation.
In addition to its role in immune response, CD226/DNAM-1 protein has also been implicated in the regulation of tumor growth and metastasis. It has been shown to promote the killing of tumor cells by NK cells and T cells, and its expression is often downregulated in various types of cancer.
Applications of Recombinant Mouse CD226/DNAM-1 Protein
Recombinant Mouse CD226/DNAM-1 Protein has a wide range of applications in both research and clinical settings. Here are some of the major applications of this protein:
1. Immunotherapy
CD226/DNAM-1 protein has been identified as a potential target for cancer immunotherapy. By enhancing the activity of NK cells and T cells, this protein can help in the elimination of tumor cells. Recombinant CD226/DNAM-1 protein can be used in combination with other immunotherapeutic agents to enhance their efficacy.
2. Vaccine development
The ability of CD226/DNAM-1 protein to enhance T cell response makes it a potential candidate for vaccine development. Recombinant CD226/DNAM-1 protein can be used as an adjuvant to boost the immune response to vaccines.
3. Biomarker for cancer diagnosis and prognosis
The expression of CD226/DNAM-1 protein has been found to be altered in various types of cancer. As a result, it can serve as a potential biomarker for cancer diagnosis and prognosis. Recombinant CD226/DNAM-1 protein can be used in diagnostic tests to detect the levels of this protein in patient samples.
4. Drug target for autoimmune diseases
CD226/DNAM-1 protein has been implicated in the pathogenesis of several autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Recombinant CD226/DNAM-1 protein can be used in drug discovery and development to identify potential inhibitors or modulators of this protein for the treatment of autoimmune diseases.
Conclusion
In summary, Recombinant Mouse CD226/DNAM-1 Protein is a crucial protein involved in immune response and has various applications in research and clinical settings. Its structure, activity and applications make it a promising target for cancer immunotherapy, vaccine development, and as a biomarker for
There are no reviews yet.